低分子肝素治疗不稳定型心绞痛的临床疗效观察

目的　探讨低分子肝素对不稳定型心绞痛的临床疗效。方法　将 69例不稳定型心绞痛患者随机分为阿斯匹林组和阿斯匹林加低分子肝素组。结果　阿斯匹林加低分子肝素组治疗两周后的心绞痛缓解率明显优于阿斯匹林对照组 (P <0 .0 5) ;2 4 h动态心电图检出的心肌缺血次数、缺血持续时间、缺血最长时间、室性早搏数、阵发性室速次数与治疗前相比两组均减少 ,但阿斯匹林加低分子肝素组明显优于阿斯匹林对照组 (P <0 .0 5) ;两组间治疗前后试管法凝血时间、部分凝血酶原时间无明显差异 ,血浆纤维蛋白原含量在阿斯匹林加低分子肝素组治疗后显著减少 (P <0 .0 5)。结论　阿斯匹林加低分子肝素对不稳定型心绞痛的临床疗效明显优于单用阿斯匹林

Low molecular weight heparin versus aspirin in the treatment of unstable angina pectoris

Objective To value the effects of low molecular weight heparin(LMWH) in patients with unstable angina pectoris (UAP).Methods A total of 69 patients with UAP were randomized to receiving aspirin (ASP group)or aspirin plus low molecular weight heparin (ASP+LMWH group) for two weeks.Results ①The clinical effective rates with the treatment were 77.4% and 97.4% respectively in ASP group and ASP+LMWH group, and was significantly higher in ASP+LMWH group than that in ASP group (P<0.05).②The minutes of longest ST episode, total ST episode and the numbers of premature contractions, ventricular tachycardia(VT) detected by Holter after the treatment reduced more significantly in ASP+LMWH group than that in ASP group (P<0.05).③After the treatment , the concentration of serum fibrinogen reduced significantly in ASP+LMWH group(P<0.05).Conclusion Treatment with ASP+LMWH during the acute phase of UAP was more efficient than ASP alone.Treatment with LMWH was efficient, safe and convenient.